|20/08/10||GEM203||FXR agonist and 5-HTR2A antagonist||NAFLD, Type 2 diabetes, obesity, dyslipidemia and hypertension||Oral||Small molecule||Preclinical||First in class single molecule having both FXR agonistic and 5-HTR2A antagonistic actions.
In DIO mice, GEM203 reduced hyperglycemia, hyperinsulinemia, insulin resistance and liver lipid contents to similar or greater extent vs metformin. GEM203 reduced the body excess weight while metformin did not.
In NASH model mice, GEM203 reduced liver excess weight, TG and TC contents, plasma ALT and AST, inflammation and collagen gene expression in the liver.
Strong IP portfolio with long expiry dates granted in major markets.
|20/08/05||GEM202||Somatostatin receptor subtype 5 (SSTR5) antagonist||Type 2 diabetes, Gallstone, Primary sclerosing cholangitis （PSC）, Inflammatory bowel disease （IBD）, short bowel syndrome （SBS）||Oral||Small molecule||IND ready||SSTR5 is primarily expressed in pancreatic ß-cells and enteroendocrine cells, and its ligand, somatostatin, negatively regulates the secretion of insulin and gut hormones (GLP-1, GLP-2, PYY, etc.). GEM202 is a selective SSTR5 antagonist and is unique owing to its dual action of elevating these hormone secretions and increasing insulin sensitivity, thereby improves glycemic control in obese and diabetic mice. In addition, GEM202 is effective in stimulating gallbladder motility and increasing bile flow, accounting for its therapeutic effects in animal models of gallstones and PSC. Thus, an additional potential application involves treatment of hepatobiliary diseases. Patents have been filed globally.||問合せ|
|20/08/01||GEM201||mRNA Vaccine Platform technology. Production of S-Protient with Immune-modulators in one construct||Coronavirus （COVID-19）; Broader Vaccine Platform||i.v.||Drug Delivery, Cell therapy||Preclinical||GEM201 utilizes TGEM055 technology loaded with antigenetic proteins as a mRNA Vaccine Platform
- Produce functional antigenetic protiens in Lymphatic organs
- Localized antigen induction at high intracellular amounts where antigen presenting cells aggregate. Co-delivery of potent Immune-modulators (GM-CSF, IL-12, etc) sumultaneously
- GEM201 is a vaccine platform
- GEM201 is critical for vaccination of elderly and immune suppresed populati
|20/07/22||GEM200||Physically damage bacterial membranes||Multidrug-resistant bacteria||i.v.||Peptide||Preclinical||A bioengineered peptide that is effective against Gram(-) bacteria and works regardless of any underlying resistance the bacteria may have against other antibiotic drugs.
GEM200 is highly efficient against Multi Drug Resistant Acinetobacter baumannii in hospital acquired infections and its unique MoA lowers the probability for development of future resistance or tolerance. GEM200 is Effective where the Standard of Care drugs fail.
- High effecacy in systemic IV administration - Rapid bactericidal MOA that avoids resistance
- Targets bacteria only – Non-toxic to human cells
- Stable peptides with T1/2=~8 hours in human plasma
|20/07/08||GEM199||A fixed dose combination of Minoxidil, resveratrol and melatonin||Alopecia / Hair Loss||Topical||Small molecule||Pre registration||Minoxidil is a potassium channel blocker that prevents hair loss by improving blood flow to the hair follicle. It also suppresses androgen receptor function and stimulates the production of prostaglandins. Resveratrol stimulates hair growth by decreasing prostaglandin D2 (PGD2) and increasing prostaglandin E2 (PGE2). Melatonin is a neurohormone involved in multiple physiological processes underlying circadian rhythm. Due to its antioxidant properties, melatonin has remarkable protective effects on cells and anti-apoptotic properties. Hence the association between melatonin and hair growth. The effect of melatonin on hair growth may be moderated by an interaction with androgens and estrogens and their receptors. Results from a clinical study demonstrated that GEM199 was more effective at stopping hair loss than Minoxidil. US patent issued, and international patents have been filed.||問合せ|
|20/07/08||GEM198||A fixed dose combination of melatonin and resveratrol||Alopecia / Hair Loss||Topical||Small molecule||Pre registration||Resveratrol stimulates hair growth by decreasing prostaglandin D2 (PGD2) and increasing prostaglandin E2 (PGE2). Melatonin is a neurohormone involved in multiple physiological processes underlying circadian rhythm. Due to its antioxidant properties, melatonin has remarkable protective effects on cells and anti-apoptotic properties. Hence the association between melatonin and hair growth. The effect of melatonin on hair growth may be moderated by an interaction with androgens and estrogens and their receptors. Results from a clinical study demonstrated that GEM198 was more effective at stopping hair loss than Minoxidil. US patent issued, and international patents have been filed.||問合せ|
|20/07/08||GEM197||A fixed dose combination of minoxidil, finasteride and latanoprost||Androgenetic alopecia||Topical||Small molecule||Phase 3||Minoxidil is a potassium channel blocker that prevents hair loss by improving blood flow to the hair follicle. It also suppresses androgen receptor function and stimulates the production of prostaglandins. Finasteride is a 5 alpha reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT), which in turn reduces the binding of DHT to the androgen receptor, thereby reducing the miniaturization of the hair follicle. Finasteride also upregulates SULT1A1, which activates the pro-drug of minoxidil into its active form - minoxidil sulfate Latanoprost is a prostaglandin analogue that has a positive stimulatory effect on the hair follicle and induces the conversion from telogen to anagen phase in the hair growth cycle. Results from a completed phase 2 study have demonstrated that GEM197 is a well-tolerated, once a day, topical fixed dose triple combination therapy that stimulates new hair growth and prevents further hair loss for the treatment of androgenetic alopecia in men 24-65 years old. The FDA has given a roadmap to start a Phase 3 clinical trial under 505(b)(2). International patents have been issued.||問合せ|
|20/06/26||GEM196||Potassium-Competitive Acid Blocker (P-CAB)||Peptic ulcer||Oral||Small molecule||Phase 2 completed||Phase 3 is ongoing.P-CABs are the best treatment with better and fater efficay for gastric acid-related gastrointestinal diseases such as gastric and duodenal ulcer, GERD, NERD, ZES and etc.
GEM196 is a potentially best-in-class P-CAB
- Faster clinical benefit in phase 2 study compared with Lansoprazole for duodenal ulcer treatment.
- Rapid and high absorption, oral bioavailability in clinical study.
- Lower toxicity and better PK, PD than TAK-438.
- Acid stability- exempt acid protection
- Longer lasting-higher concentration on target site
- Less individual differences- isoenzyme CYP2C19 metabolism tiny dependence.
|20/06/18||GEM-CDV06||A potent DNA-immunotherapy against SARS-CoV-2||COVID-19||Intra- venous Injection||In vivo CAR-T||Preclinical||DNA vector with Anti-CoV-2 Receptors inserted into our original platform (TGEM052) and delivered through liposomes into lymph nodes. The plasmid moves into the nucleus of normal T-cells and converted to CAR.
Anti-CoV-2 CAR T-cells attack the virus and diseased cells and destroy them.
|20/06/18||GEM195||A potent DNA-immunotherapy for MAGE A||Triple Negative Breast Cancer （TNBC）||Intra- muscular Injection||DNA Plasmid||Preclinical||DNA vector with MAGE A inserted into our original platform (TGEM052) and delivered into muscle cells using intramuscular injections followed by electroporation. The plasmid moves into nucleus of muscle cells and starts to over-express MAGE A, eliciting an immune response that can target MAGE A on cancer cells and destroy them||問合せ|